To the full analysis
Buyback calculator for Iovance Biotherapeutics
Iovance Biotherapeutics stock: key metrics
IOVAIovance Biotherapeutics had an operating margin of −151.1% and a return on invested capital (ROIC) of −70.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2008 | no data | no data | no data |
| 2009 | no data | no data | no data |
| 2010 | no data | no data | no data |
| 2011 | no data | no data | no data |
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | no data | no data | no data |
| 2022 | no data | no data | no data |
| 2023 | −804.5% | −38,735.0% | −37,345.4% |
| 2024 | 24.4% | −240.9% | −226.8% |
| 2025 | 34.3% | −151.1% | −148.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2008 | −100.0% | no data | −100.0% |
| 2009 | 116.9% | no data | −100.0% |
| 2010 | −100.0% | no data | −100.0% |
| 2011 | 200.0% | no data | −100.0% |
| 2012 | 29.2% | no data | −100.0% |
| 2013 | −100.0% | no data | −100.0% |
| 2014 | −26.8% | −30.5% | −25.9% |
| 2015 | −26.6% | −29.6% | −26.2% |
| 2016 | −31.7% | −31.3% | −30.8% |
| 2017 | −63.3% | −47.0% | −59.3% |
| 2018 | −26.5% | −33.1% | −25.7% |
| 2019 | −66.1% | −42.3% | −57.3% |
| 2020 | −39.5% | −40.6% | −33.8% |
| 2021 | −55.1% | −38.6% | −44.0% |
| 2022 | −79.2% | −50.0% | −59.6% |
| 2023 | −76.0% | −58.6% | −56.9% |
| 2024 | −52.4% | −75.7% | −40.9% |
| 2025 | −56.0% | −70.3% | −42.8% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2011)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.